ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.

Original languageEnglish (US)
Pages (from-to)554
Number of pages1
JournalACS Chemical Neuroscience
Issue number10
StatePublished - Oct 19 2011
Externally publishedYes


  • Depression
  • SSRI
  • antidepressant
  • major depressive disorder

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)'. Together they form a unique fingerprint.

Cite this